Download presentation
Presentation is loading. Please wait.
1
Bioenergetic Manipulation for the Treatment of Neurodegenerative Diseases
Russell Swerdlow, MD
4
Presynaptic Neuron Postsynaptic Neuron Astrocyte Capillary Lactate
Glu Glu Glu Lactate Glu Lactate Glu Glu Glu Gln Na+ Glu Gln Na+ Na+ K+ K+ Glu ADP ATP Lactate ATP ADP Glucose Astrocyte Glucose Glucose Glucose Capillary
6
Brain
7
Brain
8
Brain
9
Brain
10
Lactate No Lactate Lactate No Lactate
11
Glycolysis Glucose ADP ATP Pyruvate Acetyl CoA O2 ADP NAD+ NADH FAD
Lactate Pyruvate Acetyl CoA O2 ADP NAD+ NADH FAD FADH2 H20 ATP
12
Inferences Lactate mediates some “off target” exercise effects
Neurogenesis Bioenergetic infrastructure changes Some lactate effects mediated via mass action Lactate may act as partial “exercise mimetic” More intense exercise has bigger brain effect? Relevance to exercise-in-AD trials Different exercise regimens worth testing in AD Lactate perhaps worth testing in AD
14
(A) (B) * ** ** (C) (D) * *
15
(A) (B) * * ** * (C) (D) (E) * * * *
16
Glucose Pyruvate Lactate ADP ATP NAD+ NADH O2 ADP NAD+ NADH FAD FADH2
Acetyl CoA O2 ADP NAD+ NADH FAD FADH2 H20 ATP
17
(A) # (B) (C) * (D) (E) (F) * *
18
COO- COO- O= C HO-C-H CH2 CH2 +NADH + H+ +NAD+ Oxaloacetate L-Malate
Dehydrogenase Oxaloacetate L-Malate
19
ADP ATP Glucose Pyruvate Lactate NAD+ NADH O2 ADP NAD+ NADH FAD FADH2
Acetyl CoA O2 ADP NAD+ NADH FAD FADH2 H20 ATP
20
p<0.005 NAD+ / NADH (SEM) Control 2 mM OAA SY5Y Cell NAD+/NADH 8 7
6 5 NAD+ / NADH (SEM) 4 3 2 1 Control 2 mM OAA SY5Y Cell NAD+/NADH
21
p<0.01 Relative ATP (SEM) Control 2 mM OAA 1.4 1.2 1 0.8 0.6 0.4
0.2 Control 2 mM OAA
22
Control 2 mM OAA SH-SY5Y Cells p<0.05 p<0.0005
23
Magnetic Resonance Spectroscopy
24
p<0.05
25
p<0.05 p<0.05
26
p<0.005
27
p<0.05
28
Relative TNFa Expression
1.2 p<0.05 1 0.8 Relative TNFa Expression (SEM) 0.6 0.4 0.2 CONTROL MOUSE BRAINS OAA-TREATED MOUSE BRAINS
29
Inferences OAA increases glucose utilization
Effects through mass action-based redox change Spares respiration Alters bioenergetic infrastructures Warrants testing in neurodegenerative diseases OAA PK study OAA PD study
36
2.5 mM β-HB Control 36
37
BHB Acetyl CoA Fumarate BHB FADH2 NAD+ FAD Succinate Succinyl CoA NADH AcAc O2 ADP NAD+ NADH FAD FADH2 H20 ATP
38
Inferences Betahydroxybutyrate can support respiration
Mass action-based increase in NADH Mass action-based increase in FADH2 May facilitate complex I or complex II fluxes Compensate for a complex I defect? Changes bioenergetic infrastructures Clinical trials MCT-based AD treatment currently marketed Low carb diet suggested efficacy in MCI pilot trial Ketogenic Diet Feasibility and Retention Trial (KDFART) Diet-Induced Ketosis and Whey for AD (DIKWAD)
Similar presentations
